biostudies-literatureUnknown13(12)Mazard TInstitut National Du CancerSIRIC Montpellier Cancer<h4>Background</h4>Circulating tumor cells (CTCs) allow the real-time monitoring of tumor course and treatment response. This prospective multicenter study evaluates and compares the early predictive value of CTC enumeration with EPISPOT, a functional assay that detects only viable CTCs, and with the CellSearch^® system in patients with metastatic colorectal cancer (mCRC).<h4>Methods</h4>Treatment-naive patients with mCRC and measurable disease (RECIST criteria 1.1) received FOLFIRI-bevacizumab until progression or unacceptable toxicity. CTCs in peripheral blood were enumerated at D₀, D₁₄, D₂₈, D₄₂, and D₅₆ (EPISPOT assay) and at D₀ and D₂₈ (CellSearch^® system). Progression-free survival (PFS) and overall survival (OS) were assessed with the Kaplan-Meier method and log-rank test.<h4>Results</h4>With the EPISPOT assay, at least 1 viable CTC was detected in 21% (D₀), 15% (D₁₄), 12% (D₂₈), 10% (D₄₂), and 12% (D₅₆) of 155 patients. PFS and OS were shorter in patients who remained positive, with viable CTCs between D₀ and D₂₈ compared with the other patients (PFS = 7.36 vs. 9.43 months, <i>p</i> = 0.0161 and OS = 25.99 vs. 13.83 months, <i>p</i> = 0.0178). The prognostic and predictive values of ≥3 CTCs (CellSearch^® system) were confirmed.<h4>Conclusions</h4>CTC detection at D₂₈ and the D₀-D₂₈ CTC dynamics evaluated with the EPISPOT assay were associated with outcomes and may predict response to treatment.Cancershttps://www.ebi.ac.uk/biostudies/studies/S-EPMC8231886biostudies-literatureClinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study.PMC8231886INCa_Inserm_DGOS_125532011-049Cayrefourcq LFonck MGuimbaud RObled Sde la Fouchardiere CAssenat ELinot BMazard TSenellart HMineur LYchou MDaures JPPerriard FAlix-Panabieres CTerrebonne EFrancois EfalseClinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study.<h4>Background</h4>Circulating tumor cells (CTCs) allow the real-time monitoring of tumor course and treatment response. This prospective multicenter study evaluates and compares the early predictive value of CTC enumeration with EPISPOT, a functional assay that detects only viable CTCs, and with the CellSearch^® system in patients with metastatic colorectal cancer (mCRC).<h4>Methods</h4>Treatment-naive patients with mCRC and measurable disease (RECIST criteria 1.1) received FOLFIRI-bevacizumab until progression or unacceptable toxicity. CTCs in peripheral blood were enumerated at D₀, D₁₄, D₂₈, D₄₂, and D₅₆ (EPISPOT assay) and at D₀ and D₂₈ (CellSearch^® system). Progression-free survival (PFS) and overall survival (OS) were assessed with the Kaplan-Meier method and log-rank test.<h4>Results</h4>With the EPISPOT assay, at least 1 viable CTC was detected in 21% (D₀), 15% (D₁₄), 12% (D₂₈), 10% (D₄₂), and 12% (D₅₆) of 155 patients. PFS and OS were shorter in patients who remained positive, with viable CTCs between D₀ and D₂₈ compared with the other patients (PFS = 7.36 vs. 9.43 months, <i>p</i> = 0.0161 and OS = 25.99 vs. 13.83 months, <i>p</i> = 0.0178). The prognostic and predictive values of ≥3 CTCs (CellSearch^® system) were confirmed.<h4>Conclusions</h4>CTC detection at D₂₈ and the D₀-D₂₈ CTC dynamics evaluated with the EPISPOT assay were associated with outcomes and may predict response to treatment.2021-01-01T00:00:00Z2021 Jun2022-02-10T18:04:30.671Z2022-02-10T18:04:30.671ZS-EPMC82318863419925010.3390/cancers13122966